# PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma

> **NCT05034536** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 36 (estimated)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Infliximab
- **DRUG:** Placebo
- **DRUG:** Relatlimab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT05034536
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-07
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05034536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05034536, "PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05034536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*